Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Vyteris, Inc. (VYTR.OB) Obtains Exclusive License to Powerful New Complementary Transdermal Drug Delivery Technology

Vyteris, – developers of the revolutionary LidoSite® active transdermal drug delivery patch, disclosed details of an agreement with Georgia Institute of Technology’s Georgia Tech Research Corporation today.

The agreement grants VYTR the option to exclusively license a patented thermal ablation and microdevice fabrication technology developed at Georgia Tech, which will be used to enhance transdermal drug delivery by increasing skin permeability from delivery of high molecular weight compounds.

President and CEO of VYTR, Haro Hartounian, Ph.D., called access to these innovative technologies a real boost to the Company’s already robust transdermal capabilities, noting how the new technologies are complementary to the VYTR active transdermal smart patch technology.

Microdevice fabrication capabilities enable a new way to deliver drugs using very mild conditions which do not affect encapsulated drugs negatively or diminish their effect on targeted tissues/systems.

Professor of Chemical and Biomedical Engineering at the Georgia Institute of Technology, Dr. Mark R. Prausnitz, himself a leading agent in the field of energy-based and microneedle-based transdermal delivery systems, commented that doing away with needles helps patients stay on their medicine schedule while reducing healthcare costs across the board.

Dr. Prausnitz conveyed his understanding of how important transdermal delivery systems are in ameliorating the lives of patients the world over, by reducing the routine and often complicated process of ensuring sufficient dosage schedules are maintained to a very simple, needle-free approach.

Hartounian sees considerable potential for delivering a wider variety of drugs through the skin with the advent of new technological synergies, projecting that the advancement of combined drug delivery technologies towards clinical trial will ultimately yield substantial ROI for VYTR shareholders.

Please see disclaimer on QualityStocks website:

Disclosure: no positions